Education
About Us
Working with TipRanks
Follow Us
Esperion (ESPR)
NASDAQ:ESPR
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.16Last Year’s EPS
0.34Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 04, 2025
|% Change Since: -39.24%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements including FDA label expansions, strong revenue growth, and successful global partnerships. However, challenges such as the impact of the Medicare coverage gap and a slow start to 2025 prescription trends were also noted.Company Guidance
In the recent earnings call, Esperion Therapeutics provided guidance highlighting strong performance and strategic initiatives. The company reported a 12% sequential quarterly growth in total retail prescription equivalents (TRPEs) for its bempedoic acid products, NEXLETOL and NEXLIZET, during the fourth quarter of 2024. They have expanded payer access, covering over 173 million lives in the U.S., and increased their prescriber base by 10% to more than 25,000 healthcare providers. Esperion is also focusing on international expansion, with royalties from European partner DSE growing 9% sequentially to $9.7 million in Q4 2024 and full-year royalties up 116% to $32.6 million. The company anticipates approval and national health insurance pricing in Japan by the second half of 2025. Additionally, Esperion announced a new partnership with CSL Seqirus for commercialization in Australia and New Zealand and expects to file for marketing approval in Israel in the first half of 2025. Financially, Esperion ended 2024 with $144.8 million in cash and projects operating expenses for 2025 to be between $215 million and $235 million.U.S. FDA Approval for Expanded Labels
In March 2024, Esperion Therapeutics received U.S. FDA approval for the expanded labels of NEXLETOL and NEXLIZET, making them the only FDA-approved nonstatins to lower LDL-cholesterol and reduce the risk of myocardial infarction and coronary revascularization in both primary and secondary prevention patients.
Significant Revenue Growth
Fourth quarter 2024 total revenue was $69.1 million, an increase of 114% compared to $32.3 million in the fourth quarter of 2023. U.S. net product revenue increased by approximately 52%.
Global Expansion and Partnerships
Esperion entered into partnerships with CSL Seqirus and Neopharm Israel to commercialize NEXLETOL and NEXLIZET in Australia, New Zealand, and Israel. A new drug application was also submitted in Japan by partner Otsuka.
Strong International Performance
Royalty revenue from DSE increased 9% sequentially to $9.7 million in the fourth quarter of 2024, with full-year royalty revenue increasing 116% year-over-year to $32.6 million.
Robust Financial Strategy
Esperion executed financial transactions, including a $304.7 million royalty purchase agreement and a $150 million secured term loan facility, reshaping their capital structure and providing financial flexibility.
---
ESPR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ESPR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 04, 2025 | $1.58 | $1.77 | +12.03% |
| Nov 07, 2024 | $2.21 | $2.11 | -4.52% |
| Aug 12, 2024 | $2.02 | $1.84 | -8.91% |
| May 07, 2024 | $2.12 | $2.37 | +11.79% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Esperion (ESPR) report earnings?
Esperion (ESPR) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Esperion (ESPR) earnings time?
Esperion (ESPR) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ESPR EPS forecast?
ESPR EPS forecast for the fiscal quarter 2025 (Q1) is -0.16.
---